MedTrace Logo

Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder

NCT00644969 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2011-04-15

Study results available
· View outcomes & findings →

Summary

Study will determine whether patients with schizophrenia or schizoaffective disorder can be helped to quit smoking safely while using varenicline and receiving smoking cessation counseling.

Conditions

  • Smoking Cessation

Interventions

DRUG

placebo

Randomization 2:1 treatment to placebo

DRUG

varenicline (CP-526,555)

One week of titration up to 1mg bid and 11 weeks of dosing at 1mg bid

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2010-04-30
Completion
2010-04-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00644969 on ClinicalTrials.gov